International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 04 Issue 04 April 2024

Page No: 651-654

DOI: https://doi.org/10.47191/ijmscrs/v4-i04-11, Impact Factor: 7.949

Pediatric Considerations in Pompe Disease: A Comprehensive Review

Donaldo Emiliano Silva López[1] , Sussan Irlanda Méndez Ynostroza [2], Alma Alejandra Solano Mendoza[3], Claudia Paola Contreras Sáenz[4], Ana Isabel Díaz de León Guzmán[5], Noemí Villaseñor Alcalá[6]

[1]Hospital Centenario Miguel Hidalgo. Secretaria de salud. Aguascalientes, Aguascalientes, México.
[2]Hospital Centenario Miguel Hidalgo. Secretaria de salud. Aguascalientes, Aguascalientes, México.
[3]Hospital Civil de Guadalajara. Secretaria de salud. Guadalajara, Jalisco, México.
[4]Hospital Centenario Miguel Hidalgo. Secretaria de salud. Aguascalientes, Aguascalientes, México.
[5]Hospital Centenario Miguel Hidalgo. Secretaria de salud. Aguascalientes, Aguascalientes, México.
[6]Hospital Civil de Guadalajara. Secretaria de salud. Guadalajara, Jalisco, México.

ABSTRACT

Pompe disease, also known as glycogen storage disease type II, is a rare inherited disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA), leading to the accumulation of glycogen in various tissues, particularly muscles. While Pompe disease can affect individuals of all ages, its presentation and management in pediatric patients present unique challenges. This review aims to provide a comprehensive overview of the clinical manifestations, diagnosis, and management of Pompe disease in pediatric populations. Special considerations in the areas of respiratory support, nutrition, physical therapy, and long-term outcomes will be discussed. Understanding these aspects is crucial for optimizing the care and quality of life for children with Pompe disease.

KEYWORDS: Pompe, disease, glycogen.

ARTICLE DETAILS

Published On:
12 April 2024

Available on:
https://ijmscr.org/

INTRODUCTION

Pompe disease, also known as glycogen storage disease type II, is a rare inherited metabolic disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). This deficiency leads to the accumulation of glycogen in various tissues, particularly muscles, and can result in progressive muscle weakness and other complications. While Pompe disease can affect individuals of all ages, its presentation and management in pediatric patients present unique challenges. The aim of this article is to provide a comprehensive overview of the clinical manifestations, diagnosis, and management of Pompe disease in pediatric populations. Special considerations in the areas of respiratory support, nutritional management, physical therapy, and long-term outcomes will be discussed. Understanding these aspects is crucial for optimizing the care and quality of life for children with Pompe disease.1,2

EPIDEMIOLOGY

Pompe disease is a rare disorder with an estimated incidence of 1 in 40,000 births. However, this figure varies widely among different populations and ethnic groups. The pediatric population accounts for a significant proportion of Pompe disease cases, with early-onset forms (infantile and childhood) being more common than late-onset forms. Infantile-onset Pompe disease, the most severe form, typically presents within the first few months of life and accounts for approximately two-thirds of all pediatric cases. Childhood-onset Pompe disease, which presents after infancy but before adolescence, is less common. Late-onset Pompe disease, which manifests in adolescence or adulthood, is rare in the pediatric population but should be considered in cases where symptoms develop later in childhood. The availability of newborn screening in some regions has led to the identification of asymptomatic or minimally symptomatic cases, further highlighting the importance of understanding the epidemiology of Pompe disease in pediatric patients.3,4

CLINICAL MANIFESTATIONS

The clinical manifestations of Pompe disease in pediatric patients are diverse and can vary widely in severity. The age

of onset and rate of disease progression are key determinants of the clinical presentation.4,5

Infantile-Onset Pompe Disease (IOPD):
Presents within the first few months of life, often before 6 months of age.
Characterized by hypotonia (weak muscle tone), generalized muscle weakness, and feeding difficulties.6
Respiratory distress and failure are common due to the involvement of respiratory muscles.
Cardiomegaly (enlarged heart) and cardiomyopathy (heart muscle disease) may occur.
Failure to thrive and developmental delay are common.6

Childhood-Onset Pompe Disease (COPD):
Presents after infancy but before adolescence, typically between 1 and 5 years of age.
Clinical features include progressive muscle weakness, especially affecting the lower limbs.
Respiratory involvement is less severe compared to IOPD but can still lead to respiratory insufficiency over time.6
Cardiac involvement may occur, but it is less common and usually milder than in IOPD.
Developmental delay and failure to thrive may also be present but are less prominent than in IOPD.6

Late-Onset Pompe Disease (LOPD) in Pediatric Patients:
Rarely presents in pediatric patients but can occur in adolescence.6
Clinical features are similar to those seen in adults with LOPD and include progressive muscle weakness, predominantly affecting the proximal muscles.6
Respiratory and cardiac involvement may occur but are generally less severe and slower in progression compared to infantile and childhood-onset forms.6
Patients may present with exercise intolerance, fatigue, and difficulty climbing stairs or rising from a seated position.6

Asymptomatic or Minimally Symptomatic Cases:
With the advent of newborn screening in some regions, asymptomatic or minimally symptomatic cases of Pompe disease are being identified.6
These cases may have elevated creatine kinase levels or other biochemical markers but may not exhibit obvious clinical symptoms.6
Close monitoring is essential to detect any signs of disease progression and initiate early intervention if necessary.6
Understanding the spectrum of clinical manifestations of Pompe disease in pediatric patients is crucial for early diagnosis and appropriate management to improve outcomes and quality of life.6

DIAGNOSIS

Diagnosing Pompe disease in pediatric patients requires a multidisciplinary approach involving clinical evaluation, biochemical testing, imaging studies, and genetic testing. The diagnostic process may vary depending on the age of onset and presentation of the disease.7

CLINICAL EVALUATION

A thorough clinical assessment is essential, including a detailed medical history and physical examination.8
Symptoms such as muscle weakness, hypotonia, respiratory distress, and cardiomegaly should raise suspicion for Pompe disease.8

Biochemical Testing:
Measurement of creatine kinase (CK) levels may be elevated, reflecting muscle damage.
Definitive diagnosis is based on the measurement of GAA enzyme activity in dried blood spots or leukocytes. Reduced enzyme activity is indicative of Pompe disease.8

Imaging Studies:
Chest X-ray may reveal cardiomegaly or signs of respiratory muscle involvement.
Echocardiography can assess cardiac function and detect cardiomyopathy.8

Genetic Testing:
Molecular genetic testing of the GAA gene confirms the diagnosis and identifies disease-causing mutations.8
Genetic testing is particularly useful for family screening and prenatal diagnosis in at-risk families.8

Newborn Screening:
In some regions, newborn screening programs include Pompe disease, allowing for early detection and intervention in asymptomatic or minimally symptomatic cases.8
Early diagnosis of Pompe disease in pediatric patients is critical for initiating appropriate treatment and improving outcomes. A combination of clinical evaluation, biochemical testing, imaging studies, and genetic testing is essential for an accurate diagnosis.8

TREATMENT

The management of Pompe disease in pediatric patients requires a multidisciplinary approach aimed at addressing the various aspects of the disease, including muscle weakness, respiratory insufficiency, cardiac involvement, and nutritional needs. Treatment strategies may vary depending on the age of onset and the severity of the disease.9,10

Enzyme Replacement Therapy (ERT):
ERT with recombinant human acid alpha-glucosidase (rhGAA) is the cornerstone of treatment for Pompe disease.9,10
ERT aims to replace the deficient enzyme and reduce glycogen accumulation in tissues.

ERT is recommended for all patients with Pompe disease, including pediatric patients, and has been shown to improve muscle strength, respiratory function, and survival.9,10

Respiratory Support:
Respiratory muscle weakness is a common complication of Pompe disease, especially in infantile-onset cases.11
Non-invasive ventilation (NIV) or invasive ventilation may be necessary to manage respiratory insufficiency and prevent respiratory failure.11
Regular monitoring of respiratory function is essential to identify the need for respiratory support.11

Physical Therapy and Rehabilitation:
Physical therapy is an integral part of the management of Pompe disease, aimed at improving muscle strength, mobility, and function.11
Occupational therapy and speech therapy may also be beneficial in addressing specific functional limitations.11

Nutritional Support:
Nutritional assessment and support are important, especially in patients with feeding difficulties or failure to thrive.12
Adequate caloric intake and appropriate nutrition are essential for growth and development.13

Cardiac Management:
Cardiac involvement in Pompe disease may require specific management strategies, including monitoring of cardiac function and treatment of cardiomyopathy.14
Cardiac medications, such as beta-blockers or angiotensin-converting enzyme (ACE) inhibitors, may be prescribed to manage cardiac symptoms.14

Surgical Interventions:
Surgical interventions, such as tracheostomy or feeding tube placement, may be necessary in severe cases to manage respiratory or nutritional issues.14

Supportive Care:
Supportive care, including regular monitoring of disease progression, management of complications, and psychosocial support, is essential for optimizing the quality of life of pediatric patients with Pompe disease.14

The treatment of Pompe disease in pediatric patients is complex and requires a multidisciplinary approach. Early initiation of treatment and comprehensive care can help improve outcomes and quality of life for patients with Pompe disease.14

CONCLUSION

Pompe disease poses significant challenges in pediatric patients, requiring a comprehensive approach to diagnosis and management. Early recognition of the clinical manifestations, coupled with advances in diagnostic techniques such as newborn screening, has led to earlier diagnosis and intervention, improving outcomes for affected children. Enzyme replacement therapy has revolutionized the treatment landscape, offering hope for improved muscle function and quality of life. However, the management of Pompe disease remains complex, requiring a multidisciplinary team approach to address the diverse needs of patients, including respiratory support, nutritional management, physical therapy, and cardiac monitoring. Continued research into the pathophysiology of Pompe disease and the development of novel therapies are essential to further improve outcomes for pediatric patients with this rare disorder. By advancing our understanding and treatment of Pompe disease, we can strive to provide better care and support for affected children and their families.

REFERENCES

I. van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet. 2008;372(9646):1342–53.
II. Engel AG. Acid maltase deficiency of adult life. Trans Am Neurol Assoc. 1969;94(250–2).
III. Engel AG. Acid maltase deficiency in adults: studies in four cases of a syndrome which may mimic muscular dystrophy or other myopathies. Brain. 1970;93(3):599–616.
IV. Nigro V, Aurino S, Piluso G. Limb girdle muscular dystrophies: update on genetic diagnosis and therapeutic approaches. Curr Opin Neurol. 2011;24(5):429–36.
V. Straub V, Murphy A and Udd B. 229th ENMC international workshop: Limb girdle muscular dystrophies - Nomenclature and reformed classification Naarden, the Netherlands, 17–19 March 2017. Neuromuscul Disord. 2018;28(8):702–10.
VI. Lim JA, Li L, Raben N. Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci. 2014;6:177.
VII. Ausems MG, Verbiest J, Hermans MP, Kroos MA, Beemer FA, Wokke JH, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. 1999;7(6):713–6.
VIII. Martiniuk F, Chen A, Mack A, Arvanitopoulos E, Chen Y, Rom WN, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet. 1998;79(1):69–72.
IX. Tang H, Feuchtbaum L, Sciortino S, Matteson J, Mathur D, Bishop T, et al. The first year experience of newborn screening for Pompe disease in California. Int J Neonatal Screen. 2020;6(1):9
X. Burton BK, Charrow J, Hoganson GE, Fleischer J, Grange DK, Braddock SR, et al. Newborn screening

for Pompe disease in Illinois: experience with 684,290 infants. Int J Neonatal Screen. 2020;6(1):4.

XI. Ficicioglu C, Ahrens-Nicklas RC, Barch J, Cuddapah SR, DiBoscio BS, DiPerna JC, et al. Newborn screening for Pompe disease: Pennsylvania experience. Int J Neonatal Screen. 2020;6(4):89.

XII. Klug TL, Swartz LB, Washburn J, Brannen C, Kiesling JL. Lessons learned from Pompe disease newborn screening and follow-up. Int J Neonatal Screen. 2020;6(1):11.

XIII. Sawada T, Kido J, Sugawara K, Momosaki K, Yoshida S, Kojima-Ishii K, et al. Current status of newborn screening for Pompe disease in Japan. Orphanet J Rare Dis. 2021;16(1):516.

XIV. Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ and Hwu WL. Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. J Pediatr. 2011;158(6):1023–27.e1.